Aminoglycosides and Duct

The Effect of Aminoglycosides on Ductus in Preterm Infants

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04415554

Enrollment

Registered

2020-06-04

Start date

2021-07-31

Completion date

2022-12-31

Last updated

2021-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patent Ductus Arteriosus

Brief summary

The aim of the study is to assess the effect of aminoglycoside treatment on ductal closure in preterms

Interventions

DIAGNOSTIC_TESTechocardiography

echocardiography exam of the infant

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

30 Minutes to 3 Weeks

Healthy volunteers

Yes

Inclusion criteria

infants born at or above 32 weeks of gestation \-

Exclusion criteria

* infants who are unlikely to survive or have congenital heart defects

Design outcomes

Primary

Measure	Time frame	Description
ductal closure	3 weeks	closure of ductus arteriosus

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026